Pneumagen Targeting The Human Glycome To Block Viral Entry
COVID-19 Among Potential Uses
Emerging Company Profile: UK biotech Pneumagen expects to enter clinical studies in 2021 with a potential first-in-class glycan-targeted protein for preventing respiratory tract infections.
You may also be interested in...
The UK Government’s Therapeutics Taskforce has identified a number of drug candidates that could be used to treat COVID-19 and the first candidate is ready to enter clinical trials.
Denali Therapeutics has reported promising early clinical data in Hunter syndrome for its fusion protein, DNL310, an investigational agent that crosses the blood-brain barrier and is expected to address disease-associated CNS effects; however, some biomarker data disappointed, and there are potential competitors also under development.
Ipsen has gained worldwide development and commercialization rights to IRLAB’s dopamine D3 antagonist, mesdepotem, in levodopa-induced dyskinesia in Parkinson’s disease.